Results 151 to 160 of about 10,900 (261)

Cost-Effectiveness of Nirsevimab and Clesrovimab in Preventing Respiratory Syncytial Virus Lower Respiratory Tract Disease in Infants in the United States: A Modeling Study. [PDF]

Infect Dis Ther
Yarnoff B, Beuvelet M, Soudani S, Neary MP, Hodges EN, Chit A, Tribaldos M, Gabriel V, Musci R, Geurtsen J, Krilov LR.   +10 more
europepmc   +1 more source

Clesrovimab for the Prevention of Respiratory Syncytial Virus Lower Respiratory Tract Disease in Infants. [PDF]

J Pharm Technol
Phillips B, Jackson C, Phillips J.
europepmc   +1 more source

A cell based high-throughput screening approach for the discovery of new inhibitors of respiratory syncytial virus [PDF]

, 2013

core   +1 more source

The Evolving Landscape of Respiratory Syncytial Virus (RSV) Prophylaxis in Infants. [PDF]

Cureus
Chamarthi S, Gupta S, Chamarthi VS.
europepmc   +1 more source

Prevention of serious respiratory syncytial virus-related illness. I: Disease pathogenesis and early attempts at prevention [PDF]

, 2011
J. Michael Hoopes, Jessie R. Groothuis, Val G. Hemming Jessie   +2 more
core   +1 more source

Preclinical characterisation of the protective capacity of an anti-nucleoprotein hRSV monoclonal antibody. [PDF]

EBioMedicine
Farías MA, Andrade CA, Loaiza RA, Rodríguez-Guilarte L, Muñoz JT, Pereira-Sánchez P, Muñoz-Durango N, Pizarro-Ortega MS, Diethelm-Varela B, Pereira-Serrano A, Ramírez RA, Chávez JL, Bohmwald K, Soto JA, González PA, Bueno SM, Kalergis AM.   +16 more
europepmc   +1 more source

Palivizumab for Severe Respiratory Syncytial Virus Infection in Immunocompetent Adults: A Case Series. [PDF]

Infect Drug Resist
Zhong JY, Yeh TK, Huang HP, Ho CM, Liu PY, Fu YC.   +5 more
europepmc   +1 more source

Strengthening RSV prevention in early life through new generation strategies. [PDF]

J Pediatr (Rio J)
Mejias A, Ramilo O.
europepmc   +1 more source

Respiratory syncytial virus (RSV) antibody and small-molecule drugs: current status of clinical translation and challenges. [PDF]

Front Microbiol
Liu H, Zhong H, Liu H.
europepmc   +1 more source

Analysis of the economically justifiable price of nirsevimab to prevent respiratory syncytial virus infection in Korea. [PDF]

Hum Vaccin Immunother
Han HJ, Jang S, Dahye R, Lee H, Lee J, Bae EJ, Soudani S, Suh HS.   +7 more
europepmc   +1 more source